The career of Bernardino "Bernie" Iliakis begins with a kit, a telephone and a difficult conversation. In August 1995, the recent University of Washington graduate joined Northwest Lions Eye Bank as a technician. His work included speaking with families about consent and recovering donated eye tissue. It was technical work conducted at an emotional border, where precision had to coexist with tact and where every promise would soon pass to another pair of hands.
Thirty years later, Iliakis sits at the other end of the org chart as president and CEO of CorneaGen. The vocabulary around him has changed. There are laser-shaped grafts, preloaded delivery systems, surgeon training programs, reimbursement policy and international distribution. Yet his career has the reassuring geometry of a straight line. He did not arrive from an unrelated executive suite. He moved through the machinery.
That machinery is delicate in every sense. Donated tissue must be evaluated, prepared to exact specifications, documented, packed and delivered on time. A surgeon may ask for a graft thinner than 50 microns. A flight delay may matter. A quality rule written in a committee room may govern a decision made years later and thousands of miles away. Eye banking is a field in which compassion gets a tracking number.
Learning the system from its smallest tolerances
Iliakis earned his Certified Eye Bank Technician designation in 1996. By 1998 he was technical director, responsible for operations staff as well as eye-bank policies and procedures. Five years later he became chief operating officer of SightLife, the name adopted by Northwest Lions Eye Bank. The promotion placed clinical services and quality assurance under his watch. It also made his early experience useful in a new way: he knew how policy felt when it reached the person expected to carry it out.
The field itself was changing. For much of the twentieth century, corneal transplantation generally meant a full-thickness graft. Newer procedures required only selected layers, and the preparation of those layers increasingly moved from the surgeon to the eye bank. That shift promised consistency and saved operating-room time, but it also gave eye banks a larger role in the surgical workflow. The back room was moving closer to the operating table.
A chain of custody, care and precision
Iliakis worked on both the rules and the reality. For 15 years he served on the Eye Bank Association of America's Medical Advisory Board, which develops and revises medical standards. For another 15-year span, overlapping with that service, he inspected eye banks for the association's Accreditation Board. He also chaired the subcommittee responsible for the 2011 revision of the EBAA procedures manual. These are not glamorous assignments. They are, however, where an industry's good intentions acquire verbs, thresholds and signatures.
His technical interests extended to the femtosecond laser. CorneaGen's account of his career says multi-year work on its practical use led to a 2006 US patent application for a method of cutting corneal transplant tissue. He later joined course faculties connected with the American Academy of Ophthalmology and the American Society of Cataract and Refractive Surgery, teaching femtosecond laser keratoplasty. The technician had become a translator between research, standards and practice.
“This work is very personal for me.”Bernie Iliakis, reflecting on donation and his family
The promotion that looked like continuity
CorneaGen was formed in 2016, and Iliakis moved into the new organization as chief operating officer. That same year, the EBAA gave him its Leonard Heise Award, an honor for non-medical eye bankers whose service advances the association and its work. By then he had spent 21 years in the field. The award recognized endurance, but not mere attendance: he had served on education, procedures, bylaws and scientific-program committees, and had taught eye-banking audiences from Japan and India to Europe and the Americas.
In March 2021, CorneaGen promoted him to president as Monty Montoya moved from CEO to strategic adviser. Montoya said he had worked closely with Iliakis for more than 25 years and described him as an admired manager known for integrity and work ethic. Board chair Tom Frinzi pointed to the same combination of standing and practical experience. Public materials subsequently identified Iliakis as president and CEO, as well as a member of the board.
Joins Northwest Lions Eye Bank as a technician.
Becomes technical director, overseeing staff, policy and procedure.
Moves into the chief operating officer role at SightLife.
Transitions to CorneaGen and receives the Leonard Heise Award.
Is promoted to president of CorneaGen.
Marks 30 years in eye banking.
There is a mild corporate-comedy problem with the phrase “worked his way up.” It makes every career sound like a staircase polished for the purpose. Iliakis's route was less tidy. The organization changed names and structures. The field changed techniques. Standards thickened. Technologies that once belonged to research moved into routine workflow. His continuity was not a refusal to change. It was the context needed to decide which changes could safely become routine.
Scale, with the human unit left intact
The numbers accumulated. A 2016 industry profile credited him with overseeing more than 75,000 distributed grafts. CorneaGen later used a figure above 150,000. By late 2025, Ophthalmology Management reported more than 300,000 grafts across more than 50 countries during his career. The sequence is more informative than any one snapshot. It traces both an expanding organization and the compounding effect of a long operations career.
Under his leadership, CorneaGen has continued to move preparation closer to a surgeon's request: tissue cut to a chosen thickness, DMEK tissue prepared and preloaded, and shaped grafts made with femtosecond lasers. In June 2024, the organization commercially launched Corneal Tissue Addition Keratoplasty, or CTAK, using sterile donor-corneal inlays customized for individual cases. By April 2026, Iliakis reported 2,000 procedures by more than 150 surgeons across five countries. He presents such growth less as a victory lap than as a problem of training, evidence and access.
That instinct was visible earlier. In 2015, while serving as SightLife COO, he spoke at an award presentation for EvergreenHealth. His point was operational: donation required coordination at every step, and nurses were essential to making the process work. It is a characteristic way of distributing credit. In public updates, he repeatedly names technicians, surgeons, researchers, donor families, partner banks and recipients. The CEO appears as one junction in a crowded map.
His personal geography makes that map less abstract. An EBAA profile describes him as a first-generation American of Greek and Italian descent, originally from Spokane and resident in the Seattle area since 1990. After his father died, Iliakis arranged for his corneas to go to Crete, his father's homeland. Two people there received the donated tissue. For an executive accustomed to talking in the tens of thousands, the story reduces the unit of measurement to its proper size.
CorneaGen still shares excerpts from letters written by donor families and recipients. Iliakis has said those letters remain at the core of the work. It is easy to imagine why. Logistics can flatten a story into fields on a screen: tissue identification, processing status, destination, time. A letter restores the nouns that the database cannot hold. Father. Island. Stranger. Sight.
The operator's version of ambition
Iliakis is not a founder in the familiar mythology. He did not name the industry from a garage or arrive with a manifesto. He is an operator whose authority comes from duration, technical fluency and exposure to consequences. His degrees fit that duality: zoology, earned cum laude at the University of Washington, followed by a master's in health administration from the same institution. Biology and systems. Tissue and organization.
An EBAA portrait published when he received the Heise Award supplies a few off-duty details: travel, sports and history, with time for his wife, daughter and son listed above them all. The interests suit a person whose working life is split between movement, teams and the accumulated lessons of a field. He has lived around Seattle since 1990, long enough for the city to serve as a fixed point while the work traveled outward. Conference programs place him teaching in Tokyo; organizational reports place partner activity in India; the distribution map extends across more than 50 countries. Home stayed put. The operating radius did not.
The ambition visible in his recent updates is similarly practical. Expand access. Make outcomes more predictable. Train more surgeons. Gather stronger evidence. Preserve relationships while integrating new operations, as CorneaGen did with the Lions Eye Bank of Texas in early 2026. The April 2026 CEO update celebrated growth while conceding that the work was difficult. The sentence was brief, almost stubborn: the work is meaningful.
By September 2026, he was writing about new markets, clinical evidence and conversations planned for the ESCRS meeting in London. The organization he joined as a local technician now works through laboratories, partner banks, conferences and surgical teams across borders. Yet the governing metaphor remains the handoff. A family to a coordinator. A technician to a laboratory. A laboratory to a courier. A courier to a surgeon. A leader to the next person responsible for getting the detail right.
A 30-year career can tempt a writer into monuments. Iliakis's makes a better case for infrastructure. The achievement is not that one person touched every graft; plainly, he did not. It is that he learned how many people must touch the work, how clearly their responsibilities must be drawn, and how much trust rides on the space between them. The technician stayed for the whole journey. The chief executive still seems to be checking the handoffs.